First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial

OBJECTIVE: In newly diagnosed paediatric patients with moderate-to-severe Crohn’s disease (CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and immunomodulator therapies have failed. We aimed to investigate whether starting first-line IFX (FL-IFX) is more eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Jongsma, Maria M E, Aardoom, Martine A, Cozijnsen, Martinus A, van Pieterson, Merel, de Meij, Tim, Groeneweg, Michael, Norbruis, Obbe F, Wolters, Victorien M, van Wering, Herbert M, Hojsak, Iva, Kolho, Kaija-Leena, Hummel, Thalia, Stapelbroek, Janneke, van der Feen, Cathelijne, van Rheenen, Patrick F, van Wijk, Michiel P, Teklenburg-Roord, Sarah T A, Schreurs, Marco W J, Rizopoulos, Dimitris, Doukas, Michail, Escher, Johanna C, Samsom, Janneke N, de Ridder, Lissy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666701/
https://www.ncbi.nlm.nih.gov/pubmed/33384335
http://dx.doi.org/10.1136/gutjnl-2020-322339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666701/
https://www.ncbi.nlm.nih.gov/pubmed/33384335
http://dx.doi.org/10.1136/gutjnl-2020-322339

Ejemplares similares